Selective Activation of the Adrenomedullin Receptors in Migraine
Condition(s) studied
Investigational drug(s) / intervention(s)
Adrenomedullin: Continous intravenous infusion of 20 mL (19.9 pmol/kg/min) adrenomedulin over 20 minutes
Placebo: Continous intravenous infusion of 20 mL isotonic saline over 20 minutes
Study summary
Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.
Eligibility
Primary outcome measure(s)
- Incidence of migraine attacks — Assessed from baseline to 12 hours post-infusion of adrenomedullin or placebo
Incidence of migraine attacks, defined by either: I. Headache fulfilling criteria C and D for migraine without aura according to ICHD-3 2 * Criterion C: At least two of the following: * Unilateral location * Pulsating quality * Moderate to severe pain intensity (≥4 on an 11-point numerical rating scale) * Aggravation by cough (in-hospital setting) or avoidance of routine physical activity (out-hospital setting) * Criterion D: At least one of the following: * Nausea and/or vomiting * Photophobia and phonophobia OR II. Headache that mimics the participant's usual spontaneous migraine attacks and is treated with acute migraine (rescue) medication.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Danish Headache Center | Glostrup Municipality | Denmark | Recruiting |
More Danish Headache Center trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07451769 on ClinicalTrials.gov ↗ ← All trials in Denmark